Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 20, 2014, 07:49:15 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 620460
  • Total Topics: 46751
  • Online Today: 191
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 2
Guests: 158
Total: 160

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CROI: Apricitabine - encouraging results  (Read 1123 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
CROI: Apricitabine - encouraging results
« on: February 18, 2008, 12:48:13 PM »
MELBOURNE, Australia--(BUSINESS WIRE)--Biotechnology company Avexa Limited (ASX:AVX) announced today that it will present at the 2008 BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 3:30 PM EST at the Waldorf-Astoria hotel in New York.
Dr Julian Chick, CEO will provide a general update together with an overview of data from the Phase 2b clinical trial of apricitabine (ATC), the Company’s lead anti-HIV drug candidate, recently presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2008), held in Boston on February 4, 2008.

The key points from the scientific presentation are:

    * Both the 600mg and 800mg BID doses of ATC, in combination with optimized background antiretroviral therapy (ART), showed superior antiviral activity to 3TC in a population of treatment-experienced HIV-1-infected patients with the M184V mutation which included both first-line failures and patients with multiple prior treatment failures.
    * ATC given 600mg or 800mg BID was safe and very well tolerated over the 24-week study period.
    * No evidence of development of resistance to ATC was seen.
    * Larger, phase 3 trials of ATC in treatment-experienced patients are planned.

The results gathered to date clearly show that ATC:

    * Has an excellent safety profile at least equal to 3TC.
    * Is superior in antiviral activity to 3TC in failing patients with the M184V mutation.
    * Provides clear immunological benefit, increasing CD4 levels to higher levels than 3TC in failing patients with the M184V mutation.
    * Has not selected for resistant virus up to week 24.

“These results are extremely encouraging. In conjunction with the ongoing progress being made with the ATC development program, they provide clear indication of ATC's potential," said Dr Julian Chick, CEO.

Avexa anticipates releasing the 48 week data from the ATC Phase 2b trial during the current quarter. Thirty nine of an eligible forty patients remained on ATC therapy post the 48 week trial period.



Figure 1: Percentage of patients achieving target viral loads at Week 24

Figure 2. Time weighted average log10 change in HIV RNA from Day 0 to Week 24

Genotype Results

    * At Week 24, genotyping was possible for only 8 patients (2 in the 600mg ATC arm, 2 in the 800mg ATC arm and 4 in the 3TC arm) – of these 1 (600mg ATC), 1 (800mg ATC) and 4 (3TC) patients had M184V present.
    * No patients were found to have developed the L74V, K65R, Y115F, V75 mutations or additional TAMs during the 24-week period.
    * No evidence of resistance to ATC was seen.

Full text: http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20080211005768&newsLang=en
« Last Edit: February 18, 2008, 12:58:26 PM by John2038 »

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.